All Stories

  1. When Pulmonary Arterial Hypertension may be Associated with Portal Hypertension: A Case Report of Two Different Hepatic Disorders in One Patient with Pulmonary Hypertension
  2. Chronic thromboembolic pulmonary hypertension: clinical case and problem review
  3. COVID-19 morbidity and its influence on death rate in patients with pulmonary arterial and chronic thromboembolic pulmonary hypertension
  4. “The impact of statins addind to the fixed combination antihypertensive therapy on the arterial stiffness in patients with moderate and severe hypertension"
  5. Effect of cortisol on achieving target blood pressure levels in patients with resistant hypertension and chronic kidney disease
  6. Prognosis and risk factors for the adverse course of the disease in patients with arterial hypertension and its resistant form
  7. The impact of different angiotensin II receptor blockers on the stiffness of the large arteries and effectiveness of therapy
  8. Ventricular Function and Cardio-Ankle Vascular Index in Patients With Pulmonary Artery Hypertension
  9. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
  10. Stress and hypertension: C and H type of hypertension and causes of resistance
  11. May Measurement Month 2017–2019: an analysis of blood pressure screening results from Ukraine
  12. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  13. PVRI GoDeep: A meta‐registry merging deep phenotyping data from international PH reference centers
  14. Comparison of the effects of spironolactone and moxonidine as the fourth component of the resistant hypertension therapy on the arterial stiffness
  15. Prognostic value of low ankle-brachial index in patients with resistant hypertension
  16. Abstract P255: Resistance Hypertension And Achievement Of Target Blood Pressure Level By Continuous Positive Airway Pressure Long Therapy In Patients With Obstructive Sleep Apnea
  17. Association between H-type arterial hypertension and vascular stiffness (a pilot study)
  18. CHRONIC KIDNEY DISEASE IN PATIENTS WITH RESISTANCE HYPERTENSION AND ACHIEVEMENT OF TARGET BLOOD PRESSURE
  19. COMPARISON OF SYSTEMIC ARTERIAL STIFFNESS IN PATIENTS WITH NEW DIAGNOSED IDIOPATHIC PULMONARY AND SYSTEMIC ARTERIAL HYPERTENSION
  20. FIXED COMBINATIONS IN ACHIEVEMENT TARGET LEVEL OF BLOOD PRESSURE IN PATIENTS WITH ARTERIAL HYPERTENSION
  21. RED BLOOD CELL DISTRIBUTION IS INDEPENDENTLY ASSOCIATED WITH DAILY DIASTOLIC BP VARIABILITY
  22. RELATIONSHIPS HOMOCYSTEINE AND ARTERIAL STIFFNESS IN PATIENTS WITH H-TYPE ARTERIAL HYPERTENSION
  23. Prognostic Significance of Systemic Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Idiopathic Pulmonary Hypertension
  24. The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension
  25. Systemic Arterial Stiffness in New Diagnosed Idiopathic Pulmonary Arterial Hypertension Patients
  26. Association between arterial stiffness and obstructive sleep apnea in patients with arterial hypertension and continuous positive airway pressure therapy
  27. Ambulatory blood pressure and arterial stiffness web‐based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive patients) Registry
  28. Pulmonary hypertension register in Ukraine
  29. Influence of fixed-dose combination perindopril/amlodipine on target organ damage in patients with arterial hypertension with and without ischemic heart disease (results of EPHES trial)
  30. A17130 Comparison of factors associated with target organ damage regress on foxed dose combination perindopril/amlodipine in hypertensive patients with and without ischemic heart disease
  31. A11719 pulse-cor registry
  32. CORRELATION RELATIONSHIPS AGES, OFFICE BLOOD PRESSURE, EGFR, RENIN, ALDOSTERONE, METANEPHRYLS LEVELS IN PATIENTS WITH RESISTANT HYPERTENSION
  33. FACTORS ASSOCIATED WITH TARGET ORGAN DAMAGE REGRESS ON FIXED DOSE COMBINATION PERINDOPRIL/AMLODIPIN IN HYPERTENSIVE PATIENTS WITH AND WITHOUT ISCHEMIC HEART DISEASE
  34. HOME BP LEVELS AND ARTERIAL STIFFNESS IN PATIENTS WITH MILD TO MODERATE ARTERIAL HYPERTENSION
  35. INFLUENCE OF DIFFERENT CLASSES OF ANTIHYPERTENSIVE DRUGS ON INSULIN RESISTANCE IN PATIENTS WITH MILD AND MODERATE ARTERIAL HYPERTENSION
  36. INFLUENCE OF HYPERURICEMIA ON ELASTIC PROPERTIES OF ARTERIES IN PATIENTS WITH ARTERIAL HYPERTENSION
  37. PULSE-COR REGISTRY
  38. PULSE-COR REGISTRY
  39. Effects of metabolic syndrome on arterial function in different age groups
  40. The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with…
  41. The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension…
  42. [PP.04.17] ADDITIONAL FACTORS THAT MAY HELP IN LV DIASTOLIC FUNCTION ASSESSMENT
  43. [PP.04.16] ARTERIAL STIFFNESS, VENTRICLE-ARTERIAL COUPLING AND LV FUNCTION IN PATIENTS WITH MODERATE TO SEVERE AH
  44. [PP.22.13] EVALUATION OF EFFICACY AZILSARTAN MEDOXOMIL ON CENTRAL AORTIC BLOOD PRESSURE AND AMBULATORY BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION
  45. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial
  46. Effect of Beta - Blockers on Insulin Resistance in Patients with Hypertension and Metabolic Syndrome after 6 Months of Treatment
  47. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
  48. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia
  49. The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension — the VICTORY trial
  50. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation
  51. PS 17-64 ADDITIONAL FACTORS ASSOCIATED WITH DIASTOLIC FUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION
  52. [PP.03.03] ADDITIONAL FACTORS ASSOCIATED WITH LEFT VENTRICLE DIASTOLIC FUNCTION IMPAIRMENT IN PATIENTS WITH MODERATE HYPERTENSION
  53. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin
  54. [PP.23.22] CORRELATION CENTRAL BLOOD PRESSURE RESPONSE WITH CREATININ, EGFR AND HEART RATE AFTER RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION IN UKRAINE
  55. PS 11-55 CORRELATION RELATIONSHIP HOMA INDEX WITH BLOOD PRESSURE, HEART RATE AND LIPID IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME WITHOUT DIABETES TREATED DIFFERENT BETA BLOCKERS
  56. [PP.01.07] EFFECTS OF AZILSARTAN MEDOXOMIL ON CENTRAL AORTIC AND AMBULATORY BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION
  57. PS 17-42 FIXED DOSE COMBINATION PERINDOPRIL/AMLODIPIN AND TARGET ORGAN DAMAGE IN PATIENTS WITH ARTERIAL HPERTENSION AND ISCHEMIC HEART DISEASE
  58. [PP.13.17] GENDER DIFFERENCES IN BLOOD PRESSURE CONTROL IN HYPERTENSIVE PATIENTS
  59. [PP.13.02] IMPACT OF STATINS ON THE PERINDOPRIL/AMLODIPINE ANTIHYPERTENSIVE EFFICACY IN PATIENTS WITH HYPERCHOLESTEROLEMIA
  60. [PP.26.07] IMPACT OF VALSARTAN AND COMBINATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE ON ERECTILE DYSFUNCTION IN PATIENTS WITH MILD TO MODERATE HYPERTENSION
  61. PS 14-35 INFLUENCE OF AZILSARTAN MEDOXOMIL ON CENTRAL AORTIC BLOOD PRESSURE AND AMBULATORY BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION
  62. [PP.29.24] METABOLIC EFFECTS DIFFERENT BETA BLOCKERS DEPENDS ON PRESENTS INSULIN RESISTANCE IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
  63. [PP.13.13] ONE MONTH BLOOD PRESSURE LOWERING EFFICACY RESULTS OF A NOVEL FIRST-LINE TREATMENT IN HYPERTENSION
  64. [PP.22.17] THE LEFT VENTRICLE DIASTOLIC FUNCTION PROFILE IN PATIENTS WITH ARTERIAL HYPERTENSION AND MILDLY REDUCED KIDNEY FUNCTION
  65. Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial
  66. Predictors of high central blood pressure in young with isolated systolic hypertension
  67. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events
  68. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48
  69. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
  70. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT
  71. PP.06.19
  72. PP.01.18
  73. PP.07.33
  74. PP.18.03
  75. PP.07.38
  76. PP.20.38
  77. PP.07.36
  78. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
  79. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
  80. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension
  81. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient
  82. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline
  83. Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
  84. CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND RECENT ACUTE CORONARY SYNDROMES FROM THE EXAMINE TRIAL
  85. Edoxaban versus Warfarin in Patients with Atrial Fibrillation
  86. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
  87. Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial
  88. 2013 ESH/ESC Guidelines for the management of arterial hypertension
  89. 2013 ESH/ESC Guidelines for the management of arterial hypertension
  90. Current and future initiatives for vascular health management in clinical practice
  91. Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination
  92. HOME SELF MEASUREMENT MONITORING OF BLOOD PRESSURE: RELATION TO OFFICE AND AMBULATORY BLOOD PRESSURE MEASUREMENT: PP.14.15
  93. POSSIBILITY OF BLOOD PRESSURE CONTROL BY UKRAINIAN GENERIC DRUGS IN DIABETIC HYPERTENSIVE PATIENTS IN PRIMARY CARE SETTING: RESULTS OF MULTICENTRE OPEN TRIAL: PP.17.128
  94. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  95. Influence of losartan vs amlodipin on pulse wave velocity in patients with mild to moderate arterial hypertension
  96. Regression of left ventricular hypertrophy in patients who agreed to have repeat examination at 5 years after treatment in specialized hypertensive unit
  97. Renal function in patients with renoparenchymal arterial hypertension in dependency from treatment (3 year observation)
  98. CAROTID STRUCTURE AND HEMODYNAMIC, ITS RELATION WITH ARTERIAL BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE ARTERIAL HYPERTENSION
  99. DYNAMICS OF STATISTICAL AND EPIDEMIOLOGICAL DATA OF THE PROGRAM FOR ARTERIAL HYPERTENSION PREVENTION AND TREATMENT IN UKRAINE REALIZATION
  100. GENERAL PRACTITIONERS EXPERIENCE OF USING TELMISARTAN IN PATIENTS WITH ARTERIAL HYPERTENSION (RESULTS OF OPEN MULTICENTRAL STUDY IN UKRAINE)
  101. ?Dipper? and ?non-dipper? phenomena and heart rate variability in patients with mild to moderate arterial hypertension
  102. Antihypertensive effectiveness of the valsartan and its influence on morning surge in patients with mild to moderate arterial hypertension
  103. Target organ damage in patients with mild to moderate essential and renoparenchymal arterial hypertension
  104. Systemic arterial compliance in patients with high and low renin essential hypertension
  105. 24-HOUR BLOOD PRESSURE AND HEART RATE VARIABILITY MONITORING DURING TREATMENT BY DIFFERENT LONG-ACTING DIHYDROPYRIDINES (NITRENDIPINE, LACIDIPINE OR NIFEDIPINE)
  106. INFLUENCE OF LOSARTAN AND VALSARTAN ON BLOOD PRESSURE AND HEART RATE VARIABILITY IN MODERATE HYPERTENSION PATIENTS
  107. NEBIVOLOL INDUCED HAEMODYNAMIC CHANGES IN PATIENTS WITH CONGESTIVE HEART FAILURE CAUSED BY RENAL ARTERIAL HYPERTENSION
  108. Influence of long-term losartan monotherapy on regress of myocardial hypertrophy and left ventricular function in renal parenchymal arterial hypertension
  109. The cardiac death and the level of blood pressure in patients with congestive heart failure after progressive angina
  110. <title>Laser blood irradiation effect on electrophysiological characteristics of acute coronary syndrome patients</title>
  111. Carrier capture in quantum well embedded quantum wire structures
  112. Coulomb coupling between two-dimensional and three-dimensional electron-gas layers: Influence on electrical transport
  113. Dielectric formalism for a quasi-one-dimensional electron gas. I. Quantum transport equations
  114. Nonlinear Conductivity of a Degenerate Two‐Dimensional Electron Gas